Urgent Proton Beam Therapy With Interinstitutional Transfer for Patients With Intracranial Rhabdomyosarcoma: Report of 3 Cases.


Journal

Journal of pediatric hematology/oncology
ISSN: 1536-3678
Titre abrégé: J Pediatr Hematol Oncol
Pays: United States
ID NLM: 9505928

Informations de publication

Date de publication:
01 2020
Historique:
pubmed: 7 11 2019
medline: 1 7 2020
entrez: 6 11 2019
Statut: ppublish

Résumé

A number of cases have been reported in recent years regarding the use of proton beam therapy to mitigate adverse events affecting important cranial organs in cases of rhabdomyosarcoma at parameningeal sites. However, few reports have described the use of proton beam therapy as urgent radiotherapy for parameningeal rhabdomyosarcoma with intracranial extension. We treated 3 patients diagnosed with parameningeal rhabdomyosarcoma extending into the cranium who were assessed at other hospitals as suitable for urgent radiotherapy and transferred to our hospital for proton beam therapy. These patients comprised 2 boys and 1 girl 6 to 12 years of age at diagnosis, and proton beam therapy was started on days 5, 11, and 23 after diagnosis, respectively. Patients with parameningeal rhabdomyosarcoma extending into the cranium can be transferred to institutions equipped to perform proton beam therapy. To minimize the interval to starting therapy, medical information should be shared with institutions capable of providing such therapy as soon as the possibility of intracranial soft-tissue sarcoma is recognized. Proton beam therapy is 1 option for radiotherapy in cases of intracranial rhabdomyosarcoma.

Identifiants

pubmed: 31688631
doi: 10.1097/MPH.0000000000001620
pii: 00043426-202001000-00020
doi:

Types de publication

Case Reports Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e12-e17

Références

Ladra MM, Edgington SK, Mahajan A, et al. A dosimetric comparison of proton and intensity modulated radiation therapy in pediatric rhabdomyosarcoma patients enrolled on a prospective phase II proton study. Radiother Oncol. 2014;113:77–83.
Weber DC, Ares C, Albertini F, et al. Pencil beam scanning proton therapy for pediatric parameningeal rhabdomyosarcomas: clinical outcome of patients treated at the Paul Scherrer Institute. Pediatr Blood Cancer. 2016;63:1731–1736.
Childs SK, Kozak KR, Friedman AM, et al. Proton radiotherapy for parameningeal rhabdomyosarcoma: clinical outcomes and late effects. Int J Radiat Oncol Biol Phys. 2012;82:635–642.
Mizumoto M, Murayama S, Akimoto T, et al. Preliminary results of proton radiotherapy for pediatric rhabdomyosarcoma: a multi-institutional study in Japan. Cancer Med. 2018;7:1870.
Michalski JM, Meza J, Breneman JC, et al. Influence of radiation therapy parameters on outcome in children treated with radiation therapy for localized parameningeal rhabdomyosarcoma in Intergroup Rhabdomyosarcoma Study Group trials II through IV. Int J Radiat Oncol Biol Phys. 2004;59:1027–1038.
Spalding AC, Hawkins DS, Donaldson SS, et al. The effect of radiation timing on patients with high-risk features of parameningeal rhabdomyosarcoma: an analysis of IRS-IV and D9803. Int J Radiat Oncol Biol Phys. 2013;87:512–516.
Lucas JT, Pappo AS, Wu J, et al. Excessive treatment failures in patients with parameningeal rhabdomyosarcoma with reduced-dose cyclophosphamide and delayed radiotherapy. J Pediatr Hematol Oncol. 2018;40:387–390.
Mizumoto M, Murayama S, Akimoto T, et al. Proton beam therapy for pediatric malignancies: a retrospective observational multicenter study in Japan. Cancer Med. 2016;5:1519–1525.
National Cancer Institute, National Institutes of Health. Common Terminology Criteria for Adverse Events, version 4.0. Available at: https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf.
Nakao T, Fukushima H, Fukushima T, et al. Interinstitutional patient transfers between rapid chemotherapy cycles were feasible to utilize proton beam therapy for pediatric Ewing sarcoma family of tumors. Rep Pract Oncol Radiother. 2018;23:442–450.
Hawkins DS, Chi YE, Anderson JR, et al. Addition of vincristine and irinotecan to vincristine, dactinomycin, and cyclophosphamide does not improve outcome for intermediate-risk rhabdomyosarcoma: a report from the Children’s Oncology Group. J Clin Oncol. 2018;36:2770.
MacDonald SM, Safai S, Trofimov A, et al. Proton radiotherapy for childhood ependymoma: initial clinical outcomes and dose comparisons. Int J Radiat Oncol Biol Phys. 2008;71:979–986.
MacDonald SM, Trofimov A, Safai S, et al. Proton radiotherapy for pediatric central nervous system germ cell tumors: early clinical outcomes. Int J Radiat Oncol Biol Phys. 2011;79:121–129.
Boehling NS, Grosshans DR, Bluett JB, et al. Dosimetric comparison of three-dimensional conformal proton radiotherapy, intensity-modulated proton therapy, and intensity-modulated radiotherapy for treatment of pediatric craniopharyngiomas. Int J Radiat Oncol Biol Phys. 2012;82:643–652.
Beltran C, Roca M, Merchant TE. On the benefits and risks of proton therapy in pediatric craniopharyngioma. Int J Radiat Oncol Biol Phys. 2012;82:e281–e287.
Brodin NP, Munck af Rosenschöld P, Blomstrand M, et al. Hippocampal sparing radiotherapy for pediatric medulloblastoma: impact of treatment margins and treatment technique. Neuro Oncol. 2014;16:594–602.
Freund D, Zhang R, Sanders M, et al. Predictive risk of radiation induced cerebral necrosis in pediatric brain cancer patients after VMAT versus proton therapy. Cancers(Basel). 2015;7:617–630.
Harrabi SB, Bougatf N, Mohr A. Dosimetric advantages of proton therapy over conventional radiotherapy with photons in young patients and adults with low-grade glioma. Strahlenther Onkol. 2016;192:759–769.
Merchant TE, Hua CH, Shukla H, et al. Proton versus photon radiotherapy for common pediatric brain tumors: comparison of models of dose characteristics and their relationship to cognitive function. Pediatr Blood Cancer. 2008;51:110–117.
Park J, Park Y, Lee SU, et al. Differential dosimetric benefit of proton beam therapy over intensity modulated radiotherapy for a variety of targets in patients with intracranial germ cell tumors. Radiat Oncol. 2015;10:135.

Auteurs

Masako Inaba (M)

Departments of Pediatrics.
Departments of Child Health.

Tomohei Nakao (T)

Departments of Pediatrics.
Radiation Oncology, University of Tsukuba Hospital.
Department of Pediatrics, Dokkyo Medical University Saitama Medical Center, Koshigaya, Saitama Prefecture, Japan.

Sho Hosaka (S)

Departments of Pediatrics.

Ryoko Suzuki (R)

Departments of Pediatrics.
Departments of Child Health.

Hiroko Fukushima (H)

Departments of Pediatrics.
Departments of Child Health.

Yuni Yamaki (Y)

Departments of Pediatrics.

Takashi Saito (T)

Radiation Oncology, University of Tsukuba Hospital.

Shingo Sakashita (S)

Diagnostic Pathology.

Masayuki Noguchi (M)

Diagnostic Pathology.

Masashi Mizumoto (M)

Radiation Oncology, University of Tsukuba Hospital.
Radiation Oncology, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki Prefecture.

Hideyuki Sakurai (H)

Departments of Child Health.
Radiation Oncology, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki Prefecture.

Takashi Fukushima (T)

Departments of Pediatrics.
Departments of Child Health.

Hidetoshi Takada (H)

Departments of Pediatrics.
Departments of Child Health.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH